Business
Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025. “2025 was a pivotal year for Bionano. We transformed our business model to focus on routine users of our optical genome mapping (OGM) solutions, improved our financial profile with reduced cash burn and improved gross margins, and expanded the use and adoption of
About this update from Bionano Genomics, Inc.
[{"type":"image","alt":"Bionano Genomics","displaySize":"","headline":null,"caption":"Bionano Genomics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ylN8_Gs3_qAPxed5dOQIGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b39fec01655bcf34db9e215be03042b1","width":300,"height":61}},"lazy":false},{"type":"text","content":"SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025.","length":235,"tagName":"p"},{"type":"text","content":"“2025 was a pivotal year for Bionano. We transformed our business model to focus on routine users of our optical genome mapping (OGM) solutions, improved our financial profile with reduced cash burn and improved gross margins, and expanded the use and adoption of OGM both in the U.S. and internationally,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano. “We saw important reimbursement progress with the establishment of a second category I CPT code for OGM, this time in constitutional genetic disorders and a 47% increase in payment determination for the category I CPT code for OGM use in hematologic malignancies. We also saw significant expansion in the body of published clinical research evidence in support of using OGM as an alternative to traditional cytogenetic methods, with continued growth both in peer-reviewed publications and reported clinical research genomes. Our teams launched a major upgrade to our software and compute platforms, among other product improvements. As a result, we are entering 2026 with a strong foundation and pipeline of demand.”","length":1107,"tagName":"p"},{"type":"text","content":"Fourth Quarter 2025 Preliminary, Unaudited Financial and Business Results ","length":73,"tagName":"p"},{"type":"text","content":"For the three-month period ended December 31, 2025:","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue is expected to be in the range of $7.8 million to $8.0 million, which is at the upper end of guidance and repres...